GYNECARE INTERCEED Absorbable Adhesion Barrier
ETHICON, Inc. · Decision date Sep 24, 2025
What did the FDA decide?
FDA records P880047/S066 as a supplement to PMA P880047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 24, 2025.
FDA approval order statement
an update to the raw material inspection process at the San Lorenzo, PR manufacturing site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Sep 24, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P880047/S066
- Regulatory pathway
- PMA supplement
- Applicant
- ETHICON, Inc.
- Product code
- MCN
- Decision code
- OK30
- Decision date
- Sep 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
- Applicant
- ETHICON, Inc.
- Product code
- MCN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P880047. Subsequent supplements may change the device or its indications.
FDA decision timeline
P880047 · Original PMA
INTERCEED TC7 ABSORBABLE ADHESION BARRIER
P880047/S066 received
Application receipt date recorded by FDA.
P880047/S065 · Related supplement
GYNECARE INTERCEED Absorbable Adhesion Barrier
P880047/S066 · FDA decision
30-Day Notice
P880047/S067 · Related supplement
GYNECARE INTERCEED 3INX4IN(7.6CMX10.2CM); GYNECARE INTERCEED 5INX6IN(12.7CMX15.2CM); GYNECARE INTERCEED 3INX2IN(7.6CMX5.
P880047/S068 · Related supplement
INTERCEED Absorbable Adhesion Barrier
P880047/S069 · Related supplement
GYNECARE INTERCEED Absorbable Adhesion Barrier
P880047/S070 · Related supplement
GYNECARE INTERCEED Absorbable Adhesion Barrier
P880047/S072 · Related supplement
GYNECARE INTERCEED Absorbable Adhesion Barrier
Timeline entries are records held by MedtechLedger for P880047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P880047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ETHICON, Inc. | PMA approval | Sep 15, 1989 | FDA | |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S065 | ETHICON, Inc. | PMA supplement | Sep 4, 2025 | FDA |
| ETHICON, Inc. | PMA supplement | Oct 9, 2025 | FDA | |
INTERCEED Absorbable Adhesion BarrierP880047/S068 | ETHICON, Inc. | PMA supplement | Dec 12, 2025 | FDA |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S069 | ETHICON, Inc. | PMA supplement | Jan 15, 2026 | FDA |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S070 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juveena Hydrogel SystemP250051/S001 | Rejoni, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Womed LeafP240015/S003 | Womed Sas | PMA supplement | Oct 25, 2026 | FDA |
Juveena Hydrogel SystemP250051 | Rejoni, Inc. | PMA approval | Sep 28, 2026 | FDA |
Womed LeafP240015/S002 | Womed Sas | PMA supplement | Aug 31, 2026 | FDA |
Womed LeafP240015/S001 | Womed Sas | PMA supplement | Jan 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: P880047/S066
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




